Objective: To evaluate a new antimicrobial treatment for central venous catheters in comparison with a traditional treatment, by assessing the catheter colonization and catheter-related bloodstream infection rates in two groups of patients.
T he use of central venous catheters (CVCs) is associated with the risk of catheter colonization and catheter-related bloodstream infection (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Some authors (2) consider that bloodstream infections related to CVCs represent as much as 90% of all the hospital blood infections, and this kind of complication is a serious medical issue requiring expensive care (3) . Many attempts have been made to improve the quality of CVCs and limit the possibility of colonization and infection; these attempts have involved coating/impregnation of the catheter with various antimicrobial agents (minocycline, rifampin, chlorhexidine, silver, and silver sulfadiazine) (1, 6 -18) .
A CVC based on a new technology has been recently released. It was created with an antimicrobial material (oligon) that incorporates polyurethane, silver, carbon, and platinum. This combination should release silver ions from both the inner and outer device surfaces, limiting the possibility of bacterial colonization on the catheter and in the surrounding environment.
This study is a prospective, randomized clinical trial comparing oligon CVCs with control CVCs with a different antimicrobial treatment in terms of the rates of catheter colonization and catheterrelated bloodstream infection, in a population of patients receiving CVCs for medical or surgical pathologies.
METHODS

Patients
The Catheter Related Infection Trial (CRIT) was conducted between June 2000 and November 2001 in ten institutions. It was a multiple-center, prospective, randomized trial. Institutional review board approval was obtained according to the local policy of each institution. All patients gave informed consent. All the patients enrolled were undergoing a CVC insertion likely to require an indwelling period of Ն3 days, for either medical or surgical pathologies. We excluded anyone Ͻ18 yrs old, pregnant women, patients with a diagnosis of systemic infection at the moment of insertion, and patients with a history of allergy to any of the components of the study or control catheters.
The patients were randomly allocated to the oligon or the control group, according to a computer-generated randomization code. Randomization was in blocks of ten; each participating center was required to enroll at least ten and no more than 100 patients.
Catheters
All the patients were implanted with a double-lumen, non-heparin-bonded, 16 cm long CVC. Patients in the oligon group received a Vantex Oligon (Edwards Life Sciences, Irvine, CA) CVC, a catheter extruded from polyurethane and combined with silver, carbon, and platinum. Patients in the control group received a Multi-Med (Edwards Life Sciences) CVC, a polyurethane catheter treated with benzalkonium chloride. Both types of catheter are available for clinical use.
Insertion and Maintenance of the Catheter
The CVC could be inserted in the internal jugular, subclavian, or femoral veins. Only the catheters inserted with a new venipuncture were admitted to the study. No wire-guided change was allowed. The operator inserted the CVCs by using a sterile-barrier precaution (sterile gloves, gown, and mask for routine insertion).
The puncture site was disinfected with either chlorhexidine 0.25% and benzalkonium 0.025% or chlorhexidine 2% or povidoneiodone 7.5%. The same treatment was applied at each dressing change. The dressing always included an occlusive transparent medication and was changed every 48 hrs or more often if the dressing appeared damp, dirty, or not properly attached to the skin. The infusion catheters were changed every 72 hrs or after the infusion of blood, blood derivatives, or lipid solutions. For patients who required total parenteral nutrition, a single catheter was dedicated to it. Each stopcock was dressed with a protective medication. The CVCs were removed if no longer needed or in case of occlusion, local signs of inflammation, or systemic signs of infection.
Cultures
The CVCs were removed under aseptic conditions. A 5-cm distal segment (tip) and a 5-cm proximal segment (subcutaneous tract) were collected in sterile containers for all the CVCs. Optionally, swab samples of the surrounding skin were collected. All the samples were cultured by the roll-plate method (19) ; two institutions, after this procedure, cultured the samples by the sonication method (20) . In patients demonstrating clinical signs of bloodstream infection (fever, chill, hypotension, leukocytosis/leukopenia), peripheral blood samples were collected at the time of catheter removal and subsequently cultured. Standard microbiological methods were applied to identify the colonizing/infecting organisms.
Definitions
According to the criteria previously published (21, 22) and commonly accepted, the following definitions were applied:
Catheter colonization: growth of Ն15 colony-forming units in culture of catheter segments by the roll-plate method, or Ն1000 colony-forming units for the sonication method.
Catheter-related bloodstream infection: isolation of the same organism from the colonized catheter and from the peripheral blood of a patient demonstrating clinical signs of bloodstream infection.
Data Collection
For each patient the following variables were collected: Demographics: age, gender, weight, height, and body surface area.
Preexisting conditions: diabetes, neutropenia, presence of urinary catheters, and presence of other endovascular catheters.
Disease leading to the CVC insertion: surgical operation (cardiovascular with or without cardiopulmonary bypass, abdominal vascular, general thoracic, general abdominal, surgical operation duration, American Society of Anesthesiologists score, contaminated operation) or medical pathology (tumoral, cardiovascular, pulmonary, neurologic).
CVC positioning variables: skin preparation; difficult insertion; insertion in the ward, emergency room, operating theater, or intensive care unit (ICU); insertion through the jugular, subclavian, or femoral vein.
Post-CVC insertion variables: ICU or ward stay; length of stay; presence and duration of mechanical ventilation, parenteral nutrition, and infusional therapy; presence of antibacterial filters in the infusion catheters; blood samples from the infusion lines; and nonpreexisting tracheostomy. CVC removal variables: duration of placement and reason for removal (no longer needed, suspected catheter infection, occluded catheter, others).
Cultural variables: roll-plate or sonication method; positive culture of the tip, subcutaneous samples, or skin samples; positive blood culture; organisms identified; diagnosis of catheter contamination or catheterrelated bloodstream infection.
Patients belonging to the surgical subgroup were stratified for their infection risk according to the ASA score, the type of operation, its duration, and characteristics (23) .
Statistical Analysis
To determine the adequate number of patients to be enrolled, we conducted a power analysis based on the CVC contamination rate. According to the current literature, we considered the colonization rate of traditional benzalkonium-treated CVCs as 16% (6, 17) , assumed a 50% decrease of this rate in the oligon-treated group, and set the ␣ value to .05 and the ␤ value to .20, according to the commonly applied methods (24) . This gave us a sample size estimation of 250 patients for each group for detecting with 80% power a significant difference in the rates of colonization between the two CVCs, considering a twosided p value Ͻ.05.
Differences between groups were investigated with the following tests: Pearson chisquare and relative risk for categorical data; unpaired Student's t-test for continuous variables (univariate analysis); Kaplan-Meier actuarial analysis; and regression analyses for association between factors. A stepwise logistic regression including all the variables being significant at a p value Ͻ.10 at the univariate analysis was applied for creating a multivariate risk model. A p (two-tailed) value Ͻ.05 was considered significant. Whenever not differently stated, data are expressed as count and percentage (categorical) or as mean and SD of the mean (continuous) in text and tables. For the statistical analysis, a computerized package (SPSS Advanced Models; SPSS, Chicago, IL) was used. Two separate outcome analyses were conducted for the overall population and for the surgical population.
RESULTS
Characteristics of Patients and Homogeneity of the Groups
A total of 607 patients were enrolled during the study period, each one receiv-ing an oligon or a control catheter. Complete data were obtained from 545 patients (277 control and 268 oligon). Twenty-nine cases were missed in the control group (ten due to catheter contamination during the removal, 19 due to noncultured catheters) and 33 in the oligon group (12 due to catheter contamination during the removal, 20 due to noncultured catheters, one due to intraoperative death). The noncultured catheters were wrongly removed without notification of study coordinators. The two groups of patients were homogeneous (Table 1) with respect to demographics, risk factors, and CVC insertion and management.
Catheter Colonization
Overall Population. A total of 132 (24.2%) catheters fulfilled the criteria for catheter colonization. Of these, 82 (29.6%) were control CVCs and 50 (18.6%) were oligon-treated CVCs (relative risk, 0.63; 95% confidence interval, 0.46 -0.86; p ϭ .003). Considering the single CVC segments, oligon CVCs were colonized at the tip in 42 cases (15.6%) and control CVCs in 71 (25.6%), with a relative risk of 0.61 (95% confidence interval, 0.43-0.86, p ϭ .004). The subcutaneous tract and the skin swab cultures (performed in 354 patients, 180 control group and 174 oligon group) did not significantly differ between the two groups. No significant difference was seen with respect to catheter colonization rate as a function of Maki or sonication cultural methods.
Two time-related analysis were conducted on the catheter colonization rate. Considering the catheter colonization rate per 1000 catheter days, this was 25 (95% confidence interval, 17-33) for oligon CVCs and 41 (95% confidence interval, 32-50) for control CVCs (p Ͻ .01). Figure 1 reports an actuarial survival curve for catheter colonization in the two groups. A Kaplan-Meier analysis estimating the risk of catheter colonization according to the time the catheters were in place demonstrated that oligon catheters were significantly (p ϭ .02, log-rank test) less likely to be colonized than control CVCs.
The colonizing organisms for control and oligon catheters are listed in Table 2 . Oligon catheters were significantly less likely than control catheters to be colonized by coagulase-negative staphylococci (7.8% vs. 15.1%, relative risk, 0.52; 95% confidence interval, 0.31-0.85; p ϭ .07) and by Gram-negative bacilli (3% vs. 6.8%, relative risk, 0.43; 95% confidence interval, 0.19 -0.98, p ϭ .04). Within the group of Gram-negative bacilli, the contamination rate for Pseudomonas aeruginosa was the same in the two groups, all the difference being represented by different colonization rates for Enterobacter and other less represented organisms. Table 3) were associated with the risk of catheter colonization with a p value Ͻ0.1. With the exception of factors not present in the whole population (ICU stay and parenteral nutrition duration), they were entered into a multivariate stepwise logistic regression analysis. Three factors remained significant (p Ͻ .05) in the mul- The bacteriologic profile of the CVC cultures matched the one described for the overall population.
Many other factors (listed in
The other factors that were correlated (p Ͻ .1) with the catheter colonization likelihood are listed in Table 4 . Four factors remained significant (p Ͻ .05) at the stepwise multivariate logistic regression analysis. They are duration of operation (p ϭ .05), duration of catheterization (p ϭ .01), hospitalization in ICU (odds ratio, 2.5; 95% confidence interval, 1.42-4.5; p ϭ .001), and the use of oligon catheters (odds ratio, 0.38; 95% confidence interval, 0.22-0.68; p ϭ .001).
Catheter-Related Bloodstream Infection
Overall Population. Twenty-one patients (3.8%) had a recognized catheterrelated bloodstream infection, according to our criteria. There was no significant difference between control (4.3%) and oligon (3.3%) groups.
The rate between catheter-related bloodstream infections and catheter colonization was 0% until the fifth day of catheterization; it increased to 15.4% between days 6 and 10, to 18.5% between days 11 and 15, and to 37% for patients who had a catheterization duration Ͼ15 days, with a significant (R 2 ϭ .95) time-dependent increase at a linear regression analysis.
The main organisms responsible for bloodstream infection were coagulasenegative staphylococci (29%), Gramnegative bacilli (24%), and coagulasepositive staphylococci (14%), without significant distribution differences between groups.
Eight factors were identified as correlated (p Ͻ .1) with the presence of a catheter-related bloodstream infection at the univariate analysis: medical pathology, presence of urinary catheters, antibiotic therapy before CVC placement, placement in the ICU, hospitalization in the ICU, parenteral nutrition, nonpreexisting tracheostomy, and duration of 
DISCUSSION
Catheter-related bloodstream infection is a clinically relevant pathology that affects CVC positioning in severely ill patients. Nevertheless, its incidence is very different in different clinical scenarios. Oncologic patients receiving chemotherapy are probably the most prone to this complication, which has a reported incidence of 15% in this group (25) . Another group with a demonstrated high susceptibility to catheter-related bloodstream infection is represented by patients receiving total parenteral nutrition, with a reported rate of about 8% (15, 16) . In less selected populations, the incidence varies from 3% to 4%, reported in trauma patients (4) and in a large multicenter clinical trial (1) , to about 5% in many other studies enrolling cardiac surgical patients (12), patients hospitalized in the ICU (7) or unselected populations of patients requiring a CVC positioning (5, 14, 17) .
The catheter colonization rate is, of course, higher than the catheter-related bloodstream infection, the first being a necessary but not sufficient condition for the diagnosis of the second. Again, oncologic patients demonstrate a rate of 45% (25) , which is the highest reported, but similar rates have been reported in a general surgery ICU setting (14) , and the majority of the studies reported at least a 10% incidence. The large study of Darouiche and coworkers (1), enrolling about 800 patients, reported an incidence of 15%, but six clinical studies report an incidence Ͼ20% (5, 6, 12, 13, 26, 27) .
In our study, we found an overall catheter colonization rate of 24.2% and a catheter-related bloodstream infection rate of 3.8%. Both these data are in general agreement with the literature dealing with similar unselected patient populations. The main organisms identified were coagulase-negative staphylococci and Gram-negative bacilli. This finding is in agreement with the majority of the clinical trials in adults and children (1, 14, 20, 28, 29) .Gram-positive cocci (with 67% of coagulase-negative staphylococci) and Gram-negative bacilli represent 96% of the organisms responsible for pulmonary artery catheter colonization in cardiac surgery patients (30) .
Many comparative clinical trials are reported in the literature. Conflicting results exist for silver-coated catheters: They failed to significantly reduce both catheter colonization and catheterrelated bloodstream infection rates when compared with uncoated catheters (12, 14), but in selected population of patients (oncologic and pediatric), there are reports of a lower incidence of both the complications (25, 28) . An improved technology of silver-coated catheters, including chlorhexidine, gave the same conflicting results: Two studies demonstrated a lower rate of catheter colonization (7, 9) and one analysis stated that the use of these catheters is cost-effective and reduces the incidence of catheter-related bloodstream infections (8) ; conversely, no difference was seen for catheter colonization and catheter-related bloodstream infection rates in other clinical trials (13, 15, 16) . Benzalkonium-treated CVCs reduce the rate of catheter colonization (6) but fail to decrease the incidence of catheter-related bloodstream infections (17) .
A recently developed antimicrobial CVC impregnated with minocycline and rifampin significantly decreased the incidence of catheter colonization and catheter-related bloodstream infections compared with chlorhexidine and silver sulfadiazin-treated CVCs in a large clinical trial (1) .
Finally, a recent meta-analysis demonstrated that antimicrobial-impregnated and heparin-bonded catheters of any kind significantly decreased catheter-related bloodstream infections by 2.3% (31) .
A comprehensive analysis of comparative studies dealing with antimicrobialimpregnated CVCs is difficult, and the controversial results obtained may result from the complexity of the clinical model, which usually includes many covariates (patient's profile, pathology, duration of catheterization), and from the different kind of control CVCs that have been used (uncoated or coated with different antimicrobial agents).
The experimental variable introduced in our trial was the use of a new antimicrobial CVC (Vantex Oligon) in comparison with a traditional, benzalkoniumtreated CVC. The main characteristic of this treatment is the absence of a true coating and the inclusion of the antimicrobial agents within the structure of the material. This, according to the manufacturers, should result in a better protective action at the inner surface of the CVC and long-lasting activity. We have no knowledge of other studies dealing with this technology. Our results indicate that oligon-treated catheters significantly reduce the catheter colonization rate by about 11%, with a relative risk decrease of 37%. This action was significantly expressed against coagulase-negative staphylococci and Gram-negative bacilli, with the exception of Pseudomonas aeruginosa. When the analysis was limited to the surgical population, these results become more evident and significant, with a catheter colonization reduction of about 16% and a relative decrease of 50%.
The catheter-related bloodstream infection rate did not significantly differ between the oligon and control groups. In surgical patients, despite a reduction in relative risk of 66% in oligon group, the limited number of events did not allow us to draw any significant conclusion.
The evidence of a decrease in catheter colonization without significant decrease in catheter-related bloodstream infections is common to many comparative studies and should be carefully interpreted. Of course, the purpose of an antimicrobial-impregnated CVC is to limit catheter-related bloodstream infections rather than simply decreasing the catheter colonization rate. Anyway, it is quite clear that the catheter colonization is the first step leading, under certain conditions, to bloodstream infection. The main factor linking the two entities is time: In our analysis, no colonized catheter gave course to a bloodstream infection within the first 5 catheterization days; after that time, there was a linear increase in the rate of colonized catheters that induced a bloodstream infection, reaching a value of 37% after the 15th catheterization day. Therefore, the absence of a relationship between good results in terms of limitation of the catheter colonization rate and an equivalent limitation of the catheterrelated bloodstream infection rate may be explained by the limited number of patients receiving a CVC for a very long period of time, in ours as well as in other studies. Another point is that the usual incidence of catheter-related bloodstream infections is about 5% in nonselected populations. This means that very large cohorts of patients are required to reach a significant p value: A power analysis conducted on the basis of our results identifies this number as 7000 unselected patients or 1500 surgical patients. In this respect, surgical patients offered the best results in our study, probably because of a lower amount of catheter-independent risk factors.
Many other factors must be considered, besides the antimicrobial treatment, when analyzing a comparative study. Preventive strategies against catheter-related bloodstream infections include the use of a maximum sterile barrier, cutaneous antimicrobial/antiseptic agents, subcutaneous silver cuff, tunneling, and antiseptic hubs (32) . In particular, chlorhexidine plus benzalkonium solutions for skin preparation were more effective than povidone-iodine solutions in preventing catheter colonization in a prospective, randomized trial (33) . Unfortunately, the large majority of the institutions participating in the present trial used povidone-iodine solutions for skin preparation, and the limited number of patients receiving chlorhexidine-based skin preparations does not allow us to address this point here.
Many other risk factors have been identified for catheter colonization or catheter-related bloodstream infections: In our multivariate model, these were the duration of catheterization, the presence of a nonpreexisting tracheostomy, the duration of the operation and of hospitalization in the ICU for surgical patients (catheter colonization) and the presence of an antibiotic therapy and of a nonpreexisting tracheostomy (catheter-related bloodstream infection). In the literature, significant risk factors for catheterrelated bloodstream infections are the insertion of the CVC into the femoral or jugular vein, male gender, hospitalization in the ICU, mechanical ventilation, primary diagnosis, duration of catheterization, and number of lumen (1, 5, 29, 30) .
In the present study all the catheters were double lumen, not heparin-bonded. Occlusion of the catheter is a risk factor for catheter colonization at the univariate analysis, but, probably due to the limited amount of events (seven catheters), it is not an independent predictor at the multivariate analysis. We believe that the presence of only two lumens induced the continuous use of both lumens as infusion routes, therefore limiting the risk of catheter occlusion due to thrombosis; anyway, when the catheter is occluded, it seems more prone to colonization. This point should be considered whenever inserting a three-to four-lumen catheter, and adequate measures to reduce the risk of catheter occlusion should be applied.
The complexity of the model, together with the relatively low rate of events, makes it difficult to find a clinical benefit in terms of catheter-related bloodstream infection containment when modulating only the catheter antimicrobial properties. The most convincing study (1) finding a significant action of antimicrobial treatment in limiting catheter-related bloodstream infection enrolled about 800 patients and found a relative risk of con-O ligon treatment is effective in limiting the catheter colonization rate. trol catheters of 12; however, even in this study, only 14 patients demonstrated a catheter-related bloodstream infection, and the relative distribution of the events between the control and the treatment groups (13:1), even if significant, resulted in a very large 95% confidence interval (1.6 -91).
A final point of discussion is the cost effectiveness of routine use of impregnated catheters. In a recent meta-analysis (8), Veenstra and coworkers demonstrated that the routine use of antisepticimpregnated CVCs (chlorhexidine-silver sulfadiazine) for intensive care unit patients would save costs as long as the attributable cost of an episode of catheter-related bloodstream infection is Ͼ$687. Since the low estimate of this cost in the United States was $4869, these authors concluded that the routine use of impregnated catheters, in this scenario, is justified.
If we consider intensive care unit patients in our population (462 cases), we have a catheter-related bloodstream infection rate of 5.1% in the control group and 4% in the oligon group. The additional cost of oligon catheters is, in Italy, $15: This means that the routine use of oligon catheters would save costs as long as the cost of an episode of catheterrelated bloodstream infection is Ͼ$1363. Due to the heterogeneity of our population, a well-defined cost for an episode of catheter-related bloodstream infection is difficult to determine, but we could estimate a minimal cost of $3000: Therefore, in this setting, the routine use of these catheters may be justified.
However, this is not a comparative study and we cannot draw any conclusions about the cost-effectiveness of oligon catheters in comparison with the other commercially available impregnated CVCs.
CONCLUSIONS
Oligon-treated CVCs significantly limit catheter colonization, which is more pronounced in surgical patients, compared with conventional antimicrobial CVCs. No significant between-group difference was seen with respect to catheter-related infection rate. This last topic deserves further studies that overcome the relatively low rate of events observed in nonselected populations with larger cohort of patients and/or enrolling highrisk oncologic patients or patients receiving total parenteral nutrition.
